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To the Editors:
We read with great interest the review paper recently pub-
lished by Sapko et al. [1]. The article exhaustively presented 
current perspectives in the development of candidate multi-
ple sclerosis (MS) biomarkers in cerebrospinal fluid (CSF), 
with very interesting concepts on their diagnostic/relevant 
interpretations. 
Unfortunately, it was lacking in what it partly set out to 
do, namely a more extended review of the established, routine 
biomarkers of the disease, as well as a biophysical background 
as to how any new candidate biomarker should be evaluated. 
We believe this calls for comment. 
MS is a chronic neuroinflammatory disease of autoimmune 
type. Therefore it is not surprising that it is diagnosed, at least 
neurochemically, with CSF biomarkers reflecting autoimmune 
neuroinflammation, particularly its chronic and polyspecific 
aspects.
(i) The most common neurochemical characteristic of
chronic neuroinflammation is the intrathecal, polyspecific 
synthesis of immunoglobulins, particularly IgG, which is 
routinely assessed by a comparison of the immunoglobulins’ 
CSF-serum concentration quotients (QIg) with the biomarker 
of the blood-CSF barrier function (not to be confused with the 
blood-brain barrier), the CSF-serum concentration quotient of 
albumin (QAlb). This non-linear, hyperbolic association is best 
observed in a graphical form, on diagrams devised in the 1990s 
by H. Reiber [2], and since then known, after their inventor, 
as Reibergramms. Three of these exist, for the three routinely 
analysed CSF immunoglobulin classes: IgG, IgA, and IgM; 
MS characterises with either exclusive IgG synthesis, or its 
dominance, with c.20–30% of MS patients having concomitant 
IgM and/or IgA synthesis [3].
(ii) In addition to the quantitative analysis of the intrath-
ecal immune synthesis, they can also be assessed qualitatively, 
albeit with greater analytical sensitivity, by a comparison of 
the patterns of the polyspecific immune reaction in the CSF 
and serum in isoelectrofocusing (IEF; so called ‘olicoglonal 
IgG bands’ or OCB), as correctly pointed out by Sapko et al. 
[1].This method is currently available exclusively for IgG, 
although efforts are ongoing to extend it to other immuno-
globulin classes. According to a still valid interpretational 
guideline of the European consensus [4], five patterns of 
the OCB exist. As a practical tip, IEF can be omitted if QIgG 
> QAlb or when undoubtful intrathecal synthesis is observed on 
a Reibergramm. The diagnostic sensitivity of the intrathecal
synthesis of IgG in MS is so high that its absence practically
excludes (with minor exceptions) a diagnosis of chronic
neuroinflammation of the autoimmune type. Its diagnostic
specificity, though, is much worse, particularly among differ-
ential diagnoses of chronic neuroinflammations.
(iii) Polyspecific immune reaction in the central nervous
system is perhaps best reflected (and most commonly misin-
terpreted) by quantitative analysis of the intrathecal synthesis 
of the immunoglobulins specific against a vast range of – caus-
atively unrelated – antigens, such as neurotrophic viruses, with 
antibodies against measles (M), rubella (R), varicella-zoster 
(Z), and herpes simplex (H) playing the most important dia-
gnostic roles. A simultaneous analysis of CSF-serum specific 
indices of the antibodies, in the IgG class, against the four 
viruses is commonly referred to as the ‘MRZH Reaction’. This is 
predictive of autoimmune-type chronic inflammatory disease, 
even at the first clinical manifestations [5, 6].
(iv) A mild, if any, blood-CSF barrier dysfunction is usu-
ally observed in MS, with QAlb rarely larger than 25 × 10-3. 
Similarly, mild CSF pleocytosis is frequently observed, but the 
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cell count rarely exceeds 30 cells/mm3, and they are almost exclu-
sively mononuclear. Larger values of one of the two analytes in-
dicate strongly against MS (apart from cases of a comorbidity, of 
course), hence playing an important differential diagnostic role.
(v) On top of that, in the search for novel candidate bio-
markers it is of crucial importance to consider blood-CSF 
protein diffusion mechanisms, directly related to the issues of 
protein biophysics discussed above in (i). This is particularly 
important where a novel candidate CSF biomarker is of mixed 
blood- and brain-derived origin. Ignoring molecular-sized 
dependent blood-CSF diffusion, particularly in cases of an 
even slightly dysfunctional blood-CSF barrier, leads to serious 
misinterpretation of the source of the candidate biomarker, 
and consequently its diagnostic validity.
Taken together, we believe that it is extremely important for 
neurologists, as well as for clinical chemists involved in CSF anal-
ysis, to properly understand the role of the CSF in the diagnosis 
of MS, as well as in a range of other neurological conditions. 
The importance of CSF analysis in current neurology is 
reflected by the diagnostic guidelines published by societies 
of neurologists, such as that of Germany [7], though unfor-
tunately not (yet) adopted in some countries. 
A thorough analysis of routine CSF biomarkers is not only 
of fundamental help in caring for the patient, but also provides 
a solid basis for the search for novel candidate biomarkers such 
as those reviewed by Sapko et al. [1].
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